Macro First

No it’s down 50% because biotech is in the shitter. Go overlay LABU and QURE, they have a 0.81 weekly correlation since June. Even tighter correlation with GHRS. Franchise asset with juiced up options and low share float will do that.

The significance of this can't be overstated re: $QURE AMT-130. Punchline → AMT-130 will get approved overseas and the U.S. will continue to fall behind in the biotech race globally. First, some relevant dates: - This presentation: Last week, Mar 30, 2026 - 4y cohort cutoff: Jun 2026 - 4y data readout: ~Sep 2026 Why this presentation is so important: > Dr. Tabrizi obviously, and of course, hasn't seen the 4y dataset yet... > ...BUT, she's a clinician — she sees these patients on an *ongoing* basis. > Dr. Tabrizi would not be speaking w/ this level of conviction if she were seeing deterioration leading into the 4y assessment. > Remember — she's been involved in many HD trials, and she doesn't sugarcoat results. For example, in Mar 2021, she publicly stated that Roche’s P3 tominersen (Gen HD1) did not work. [1] Dr. Tabrizi — one of the world's leading HD researchers — continues to pound the table: "... and two people [from the high-dose AMT-130 cohort] — and this is unheard of — went back to work. Having medically retired, and then gone back to work." [2] This is how the U.S. falls behind. Cc @fjeg1987 @JTLonsdale — @SenGillibrand | @lukaske @SenRickScott | @ClareLattanze @SenRonJohnson | @GraceCarnathan @RepAuchincloss | @GeorginaBurros — #FDA $XBI

quick chat with the Stat team about rare disease and fda. adam asked what i had to say about those who argue vinay brought rigor back to fda and that patient advocates had too much influence. what i wish i articulated better is what people who have been involved in rare disease trials will tell you is even if u have a cure, u often can't run a gold standard randomized trial to prove it if a disease is too rare, heterogenous, or slow. patient advocacy leaders understand this intimately well and regulators would make better decisions if they listen more to them rather than less.

My meeting with Senator Johnson's office today went well! We are moving in the right direction. 💪💙

Dr Sarah Tabrizi, the foremost expert in Huntington's Disease research and treatment had the attached to say during a 3/30/2026 presentation at Royal College of Physicians with regard to @uniQure_NV $QURE AMT130 gene therapy treatment. This is the same treatment that @DrMakaryFDA and @VPrasadMDMPH said "is a failed therapy" because they are in the back pocket of @johnarnold who met with FDA officials on 07/08/2025 to discuss "Items of Mutual Interest". What could a well known short seller who made his fortune at Enron know about FDA issues? fda.gov/news-events/public-c… Then John Arnold also met with FDA officials again 03/03/2026 to discuss "Collaboration Opportunities". Again, what does this hedge fund billionaire have to do meeting with FDA officials to discuss Corruption, I mean Collaboration Opportunities? Why is he influencing FDA decisions? fda.gov/news-events/public-c… Who should we trust? The world's foremost expert on HD Research or a billionaire who is influencing FDA decisions for some unknown reason? Time for the investigations to begin to hold those accountable. @SenRonJohnson @SenRickScott @RepAuchincloss @adamfeuerstein @l_e_whyte @temple_west @laurencurehd @JRenz0418 @BeckyQuick @MariaBartiromo @docrodwong @LuckyPenguin10 @SECGov @POTUS @LauraLoomer @SenateAging @SenBillCassidy @SenRandPaul @WhiteHouse @SusieWiles @StevenCheung47 @StevenCheung @Scavino47 @PressSec @SecKennedy @MariaBartiromo @FoxNews @bariweiss @60Minutes @CNBC @WSJopinion @WSJ @statnews @BillAckman @Loftus @MartinShkreli

Possibly even more interesting was the call out on TFC, saying it wasn’t due to any outliers, basically saying all the patients showed stuff that wouldn’t be normal for these patients. Placebo doesn’t work on TFC. Not to mention, at 3 years, from year 2 to 3, it actually was improving, we shall see if that trend continues but definitely was “interesting” as Tabrizi said.